These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8269302)

  • 21. [Risks and side effects in treatment of supraventricular tachycardia].
    Lüderitz B
    Z Gesamte Inn Med; 1993 Sep; 48(9):459-65. PubMed ID: 8212752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aggravation of arrhythmia by antiarrhythmic drugs, and the important role of underlying ischemia.
    Podrid PJ; Fogel RI
    Am J Cardiol; 1992 Jul; 70(1):100-2. PubMed ID: 1615848
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical evaluation of new anti-arrhythmia drugs after the CAST (Cardiac Arrhythmia Suppression Trial) study].
    Meinertz T; Zehender M; Hohnloser SH
    Z Kardiol; 1992; 81 Suppl 4():145-9. PubMed ID: 1290291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    Flaker GC; Blackshear JL; McBride R; Kronmal RA; Halperin JL; Hart RG
    J Am Coll Cardiol; 1992 Sep; 20(3):527-32. PubMed ID: 1512329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of exercise testing in evaluation of arrhythmias.
    Podrid PJ; Venditti FJ; Levine PA; Klein MD
    Am J Cardiol; 1988 Oct; 62(12):24H-33H. PubMed ID: 3052006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indications for antiarrhythmic suppression of ventricular arrhythmias: a definition of life-threatening ventricular arrhythmias.
    Morganroth J
    Am J Cardiol; 1993 Aug; 72(4):3A-7A. PubMed ID: 8346724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
    Peters RW; Mitchell LB; Brooks MM; Echt DS; Barker AH; Capone R; Liebson PR; Greene HL
    J Am Coll Cardiol; 1994 Feb; 23(2):283-9. PubMed ID: 8294678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ventricular arrhythmia in congestive heart failure.
    Podrid PJ; Fogel RI; Fuchs TT
    Am J Cardiol; 1992 Jun; 69(18):82G-95G; discussion 95G-96G. PubMed ID: 1626494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inducible ventricular arrhythmias and sudden death during vasodilator therapy of severe heart failure.
    Stevenson WG; Stevenson LW; Weiss J; Tillisch JH
    Am Heart J; 1988 Dec; 116(6 Pt 1):1447-54. PubMed ID: 3195428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical approach to antiarrhythmic therapy in patients with ventricular arrhythmia.
    Reddy CP; Arnett JD
    J La State Med Soc; 1989 May; 141(5):45-8. PubMed ID: 2659710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias.
    Steinbeck G; Andresen D; Bach P; Haberl R; Oeff M; Hoffmann E; von Leitner ER
    N Engl J Med; 1992 Oct; 327(14):987-92. PubMed ID: 1355595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The pro-arrhythmic effects of anti-arrhythmia agents].
    Haverkamp W; Wichter T; Chen X; Hördt M; Willems S; Rotman B; Hindricks G; Kottkamp H; Borggrefe M; Breithardt G
    Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What have clinical trials taught us about proarrhythmia?
    Skanes AC; Green MS
    Can J Cardiol; 1996 Apr; 12 Suppl B():20B-26B. PubMed ID: 8616725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aggravation of ventricular arrhythmia. A drug-induced complication.
    Podrid PJ
    Drugs; 1985; 29 Suppl 4():33-44. PubMed ID: 3924550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiarrhythmic drug therapy for congestive heart failure with focus on moricizine.
    Podrid PJ; Beau SL
    Am J Cardiol; 1990 Feb; 65(8):56D-64D; discussion 68D-71D. PubMed ID: 2407092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proarrhythmia.
    Friedman PL; Stevenson WG
    Am J Cardiol; 1998 Oct; 82(8A):50N-58N. PubMed ID: 9809901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent.
    Sadanaga T; Ogawa S
    J Am Coll Cardiol; 1994 May; 23(6):1378-81. PubMed ID: 8176096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiarrhythmic drug therapy in congestive heart failure. Indications and complications.
    Ravid S
    Postgrad Med; 1991 Dec; 90(8):99-102, 105. PubMed ID: 1749742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proarrhythmic responses during electrophysiologic testing.
    Horowitz LN; Greenspan AM; Rae AP; Kay HR; Spielman SR
    Am J Cardiol; 1987 Apr; 59(11):45E-48E. PubMed ID: 3578040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral antiarrhythmic agents for ventricular arrhythmias.
    Meissner MD; Nestico PF; Morganroth J
    Clin Ther; 1986; 8(6):595-604. PubMed ID: 3539346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.